virus covid-19 vaccine DNA

Predictive Oncology joins race to develop Covid-19 vaccine

Reading now: 588
www.pharmaceutical-technology.com

Predictive Oncology has joined the race to develop a Covid-19 vaccine with the acquisition of Soluble Therapeutics, followed by collaboration and licensing of a new nanoparticle vaccine technology platform.

The vaccine technology, based on a self-assembling nanoparticle called NSP1, has surface properties enabling the rapid design and display of viral receptor stems for virtually all viruses.

In previous studies, vaccines with NSP10-based Nanoparticles generated significantly high titers against a herpes viral protein called glycoprotein D in rabbits.

The high levels of titers were observed with a simple injection and a second booster, without adjuvants or transfection agents.

Read more on pharmaceutical-technology.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA